Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) EBITDA
Gilead Sciences, Inc.'s EBITDA for fiscal 2025 was $12.8B, up 188.6% from $4.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $262.0M. Over the past ten years it has ranged from $4.4B (fiscal 2024) to $23.3B (fiscal 2015); the current reading is higher than 73% of that period. Gilead Sciences, Inc. ranks 16th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $12.8B | 188.60% |
| FY2024 | $4.4B | (56.99%) |
| FY2023 | $10.3B | 9.17% |
| FY2022 | $9.4B | (21.18%) |
| FY2021 | $12.0B | 115.60% |
| FY2020 | $5.6B | (2.46%) |
| FY2019 | $5.7B | (40.90%) |
| FY2018 | $9.6B | (37.51%) |
| FY2017 | $15.4B | (17.99%) |
| FY2016 | $18.8B | (19.32%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$9.7B | — |
| Mar 2026 | $3.3B | 22.58% |
| Dec 2025 | $2.7B | (33.44%) |
| Sep 2025 | $4.0B | 26.79% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S compare | $26.5B |
| NVS Novartis AG compare | $22.5B |
| PFE Pfizer Inc. compare | $20.4B |
| AZN AstraZeneca PLC compare | $20.3B |
| AMGN Amgen Inc. compare | $16.5B |
| BMY Bristol Myers Squibb Company compare | $15.1B |
| MRK Merck & Co., Inc. compare | $13.7B |
| GSK GSK PLC Sponsored ADR compare | $12.8B |
| GILD Gilead Sciences, Inc. | $262.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on GILD
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement